Altor sells Ferrosan to Pfizer

The investor acquired a stake in the company in 2005. Since the initial investment FCH's EBITDA has increased from DKK 147m to DKK 302m in 2010, representing an annual increase of 15%. The investor has supported the company through focusing on key brands in core markets, improving the operational efficiency and a reorganisation of the governance structure.

Altor will maintain its involvement in Ferrosan Medical Devices.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Viktor Lundvall on +44 20 7004 7476 or viktor.lundvall@incisivemedia.com

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Healthcare
• Exits
• Altor
• Partial sale
• Denmark